View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
July 12, 2011

Onconova Partners SymBio to Develop Rigosertib

Onconova Therapeutics and SymBio Pharmaceuticals have signed a licence agreement to develop and commercialise rigosertib in Japan and Korea. Rigosertib, a styryl benzyl sulfone, is a small molecule inhibitor of critical pathways important in the growth and proliferation of cancer cells.

By cms admin

Onconova Therapeutics and SymBio Pharmaceuticals have signed a licence agreement to develop and commercialise rigosertib in Japan and Korea.

Rigosertib, a styryl benzyl sulfone, is a small molecule inhibitor of critical pathways important in the growth and proliferation of cancer cells.

Onconova is conducting late-stage clinical trials with rigosertib in the US, Europe and India for the treatment of myelodysplastic syndromes and solid tumours.

Under the terms of the agreement, Onconova will receive an upfront payment and development milestones tied to the progress of rigosertib, as well as sales milestone payments and royalties based on net sales.

In addition to the intravenous product, an oral formulation of rigosertib is being developed for frontline myelodysplastic syndromes and other indications.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology